, a bio/informatics shared resource is still "open for business" - Visit the CDS website


W. Rathmell
Last active: 11/27/2019

  1. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, Wallen EM, Crane JM, Kim WY, Rathmell WK, Godley PA, Whang YE (2012) BJU Int 110(11 Pt B): E721-6
    › Primary publication · 23016517 (PubMed)
  2. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, Nielsen ME, Rathmell WK (2012) Eur Urol 61(2): 258-68
    › Primary publication · 22030119 (PubMed) · PMC3244546 (PubMed Central)
  3. Kidney cancer. Linehan WM, Rathmell WK (2012) Urol Oncol 30(6): 948-51
    › Primary publication · 23218074 (PubMed) · PMC4419144 (PubMed Central)
  4. Carcinoma in a cadaveric transplant kidney. Manvar AM, Rathmell WK, Ferguson J, Pruthi RS, Nielsen ME, Wallen EM, Nolan N, Raynor MC (2012) Urology 79(4): 758-60
    › Primary publication · 22014593 (PubMed)
  5. Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma. Teng BL, Hacker KE, Chen S, Means AR, Rathmell WK (2011) Mol Oncol 5(5): 465-74
    › Primary publication · 21764651 (PubMed) · PMC3194764 (PubMed Central)
  6. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell WK, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA (2011) Urol Oncol 29(6): 608-13
    › Primary publication · 20022268 (PubMed)
  7. Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development. Rasmussen N, Rathmell WK (2011) Curr Clin Pharmacol 6(3): 199-206
    › Primary publication · 21470103 (PubMed)
  8. Basic research in kidney cancer. Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A (2011) Eur Urol 60(4): 622-33
    › Primary publication · 21741760 (PubMed) · PMC4877128 (PubMed Central)
  9. A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions? Kurpad R, Kim W, Rathmell WK, Godley P, Whang Y, Fielding J, Smith L, Pettiford A, Schultz H, Nielsen M, Wallen EM, Pruthi RS (2011) Urol Oncol 29(4): 378-82
    › Primary publication · 19576797 (PubMed)
  10. VHL and PTEN loss coordinate to promote mouse liver vascular lesions. Chen S, Sanford CA, Sun J, Choi V, Van Dyke T, Samulski RJ, Rathmell WK (2010) Angiogenesis 13(1): 59-69
    › Primary publication · 20221685 (PubMed) · PMC2872996 (PubMed Central)